What Trutakna's Approval Means for Specialty Launches

The FDA has granted accelerated approval to Vera Therapeutics' Trutakna (atacicept-vymj) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, the agency and the Brisbane California-based biotech announced July 7, 2026. Trutakna is the first approved therapy that targets both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), cytokines involved in the survival and maturation of the immune cells that drive the disease.¹

The approval adds another entrant to the market for targeted IgAN therapies. Beyond its novel mechanism, Trutakna's launch highlights the growing role of specialty pharmacy distribution, patient support programs, and reimbursement services in bringing targeted therapies to patients with IgAN.

“The approval of Trutakna as the first and only BAFF and APRIL inhibitor for IgAN marks an important milestone, and we believe it has the potential to meaningfully transform the treatment landscape. We believe Trutakna offers a novel approach to addressing this serious disease and has the potential to advance care for patients with this significant unmet medical need,” said Marshall Fordyce, MD, founder and CEO of Vera Therapeutics, in a release.²

How Does Trutakna Work?

Trutakna is a soluble recombinant fusion protein based on the human transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL. By blocking these signaling molecules, the therapy disrupts the B-cell activity that drives production of galactose-deficient IgA1 (Gd-IgA1) and the autoantibodies that recognize it. Together, these molecules form immune complexes that accumulate in the kidneys, triggering the inflammation and progressive damage characteristic of IgA nephropathy. The therapy is self-administered by a 150-mg autoinjector once weekly.²

By simultaneously inhibiting BAFF and APRIL, Trutakna is designed to target upstream immune pathways involved in IgAN pathogenesis. According to Vera, it is the first FDA-approved therapy to inhibit both cytokines.

The approval is supported by a prespecified 36-week interim analysis of the ongoing Phase 3 ORIGIN 3 trial, in which patients receiving Trutakna achieved a 46% reduction from baseline in proteinuria and a statistically significant 42% reduction versus placebo (p<0.0001). Vera also reported a 68% reduction in Gd-IgA1, a secondary, non-multiplicity-adjusted endpoint.² The therapy received Breakthrough Therapy designation and Priority Review by the FDA.¹

How Will Patients Get and Stay on the Drug?

Trutakna is dosed at 150 mg and self-administered once weekly using an autoinjector at home, positioning the therapy outside the infusion suite and shaping how it will move through specialty pharmacy channels.

The weekly autoinjector format aligns with the specialty pharmacy and hub-service infrastructure commonly used to support self-administered specialty biologics. As more specialty biologics shift toward home administration, integrated patient support programs will help reduce access barriers and improve treatment persistence.

Vera is launching the therapy alongside TRUTAKNA TRU SUPPORT, a patient support program that the company says will provide insurance coverage assistance, financial support for eligible patients, and educational resources.² Commercially insured patients who qualify may pay as little as $0 out of pocket through the company's copay assistance program, according to Vera.

What Comes Next for the Approval?

Because Trutakna received accelerated approval based on reduction in proteinuria, according to the FDA, continued approval may be contingent upon verification and description of clinical benefit that the therapy slows long-term kidney function decline in the ongoing blinded ORIGIN 3 study.

Vera expects estimated glomerular filtration rate data from the confirmatory trial in the third quarter of 2026. FDA likewise noted that continued approval may be contingent upon confirmation of clinical benefit through the study.

What Does This Mean for Patients?

The approval expands treatment options for patients with IgAN, a disease that has historically relied on supportive care.

If confirmatory data demonstrate long-term kidney benefit, Trutakna could strengthen the case for targeting upstream immune pathways as a treatment approach in IgAN.

From a commercialization standpoint, the launch underscores the importance of comprehensive patient support programs to assist patients receiving home-administered therapies as manufacturers bring more targeted biologics to market.

References

1. U.S. Food and Drug Administration. FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy. Published July 7, 2026. Accessed July 7, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy
2. Vera Therapeutics. Vera Therapeutics Receives FDA Accelerated Approval of TRUTAKNA™ (atacicept-vymj), the First and Only BAFF/APRIL Inhibitor for IgA Nephropathy. Published July 7, 2026. Accessed July 7, 2026. https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-receives-fda-accelerated-approval-trutaknatm